Management of Destiny Pharma, the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their expectations for 2022 and beyond.
#TRLS #TrellusHealth #smallcaps #smallcapsinvesting #VoxMarkets #LondonStockExchange #FinancialNews #CompanyNews #trading #investing #stocks #shares #money
